Electronic Drug Delivery Devices Market Size & Share 2025 - 2034

Electronic Drug Delivery Devices Market Size

The global electronic drug delivery devices market size was valued at around USD 64.7 billion in 2024 and is estimated to grow at 8.5% CAGR from 2025 to 2034. Electronic drug delivery devices are advanced systems in the medical field meant to deliver medication dosages electronically and logged as needed either manually initiated by the user or automatically programmed, with dosage events often recorded for monitoring and compliance purposes. These devices have sensors and microprocessors which instrument and connect to make optimal drug delivery using real time physiological data and therapeutic protocols that have already been set beforehand.

The worldwide increase in chronic ailments significantly accelerates the need for electronic systems that administer medication. The World Health Organization (WHO) estimates that approximately 74% of deaths worldwide result from noncommunicable diseases (NCDs) with 17 million people dying prematurely each year. Diabetes, cancer, cardiovascular diseases, and respiratory disorders are projected to increase to the 90 million annual deaths by 2050, which estimates to about 90% rise in absolute numbers since 2019. There is a growing need to manage these complex and interrelated health issues that require continuous multifaceted medication strategies.
 

Conventional methods of drug delivery do not ensure adherence, accuracy, and continuity of care, or where there is no patient compliance with the prescribed treatment regimen, electronic drug delivery devices overcome these barriers with programmable, precise, and patient-centric medication delivery solutions. These devices not only improve therapeutic outcomes through consistent dosing but also reduce hospitalization and monitoring costs, making them particularly beneficial for both high-income and resource-limited healthcare systems.
 

Moreover, the worldwide surge in the aging population serves as a motivation for the growth of the electronic drug delivery devices market. Elderly patients usually undergo long-term treatment for chronic medical conditions such as cancer, cardiovascular diseases, diabetes, and chronic kidney disease (CKD) which increase in number with age. Most of these elderly patients require sophisticated, continuous, user-friendly drug delivery systems.
 

According to the United Nations (UN) estimates, the number of people aged 65 years and above is projected to increase from 761 million in 2021 to 1.6 billion by 2050. This shift has put continuous strain on healthcare systems to improve medication adherence, decrease avoidable hospital stays, and facilitate elderly population shift to homecare. Thus, healthcare providers and manufacturers are increasingly using electronic drug delivery devices with programmable dosing, remote monitoring capabilities, and ease of use tailored for elderly patients. These devices help streamline therapy regimen, mitigate risk for under- or over-dosing, and improve clinical outcomes which supports market growth in the long run.
 

Electronic Drug Delivery Devices Market Trends

• The deployment of sophisticated technologies and connectivity features into electronic drug delivery devices is transforming patient management. For instance, devices such as insulin pumps and patch injectors now include Bluetooth and mobile app synchronization, enabling real-time dosage tracking and remote physician monitoring. This advancement enhances patient adherence and therapy personalization.
   
• Examples include the Omnipod 5 by Insulet, a tubeless wearable insulin pump that integrates with the Dexcom G6 and can be controlled via a smartphone app; the t:slim X2 Insulin Pump by Tandem Diabetes Care, which uses Control-IQ technology and connects to the t:connect mobile app for continuous data sharing; and the YpsoPump by Ypsomed, which synchronizes with the mylife app to allow for mobile-based insulin management and physician access via cloud platforms. These devices exemplify the growing shift toward connected, patient-centric drug delivery solutions.
   
• Furthermore, wearable and portable injectors have emerged to fulfill the demand for stem administered therapies for chronic ailments such as diabetes, rheumatoid arthritis, and multiple sclerosis. Ypsomed and West Pharmaceutical Services now offer wearable large volume injectors which permit home subcutaneous infusion of biologics, minimizing the need for clinical visits.
   
• Additionally, AI has been gaining popularity in optimizing drug delivery systems and personalizing dosing schedules. Smart delivery systems embedded with algorithms can evaluate patient-reported outcomes and biometrics in real-time to modify doses automatically, minimizing risks and increasing effectiveness.
   
• Also, the focus on compliance and product safety is changing device development workflows. One of the impacts is the FDA’s 21 CFR Part 820 Quality System Regulation (QSR) and the European Union’s Medical Device Regulation (MDR); that demands better risk management and requires more detailed design and post-market surveillance documentation for drug delivery systems.
   
• Further, a move toward lowered design eco-footprint is becoming noticeable. Certain manufacturers are working on an electronic delivery device with reusable parts and recyclable cartridges; this aligns with global sustainability and healthcare provider demands for waste reduction.
   

Electronic Drug Delivery Devices Market Analysis

Based on product, the market is segmented into smart infusion pumps, smart metered dose inhalers, implantable drug delivery devices, smart transdermal patches, and other products. The global market was valued at USD 64.7 billion in 2024. The implantable drug delivery devices segment dominated the market with the largest revenue share of 33.6% in 2024.
 

• Increasing occurrence of chronic conditions including cancer, cardiovascular diseases, as well as diabetes that demands long-term, controlled, and often site-specific drug delivery is on rise. Continuous therapeutic dosing provided by implantable drug delivery devices minimizes patient non-compliance and improves clinical outcomes. An example is the cancer’s growing burden, which is propelling the adoption of implantable chemotherapy ports and targeted delivery systems. In 2022, over 19.9 million new cases of cancer were diagnosed globally (GLOBOCAN), driving the demand for implantable drug delivery devices.
   
• In addition, the implementation of programmable pumps, targeted drug-eluting implants, and biodegradable implants have expanded to other therapeutic areas such as pain management, hormonal therapy, and neurology. These areas are further enhanced by new systems, such as Medtronic’s SynchroMed II intrathecal drug delivery system to improve patient outcomes by precise dosing and sustained drug release.
   
• Further, global shift towards value-based care and outpatient services aligns with the need for chronic disease management, which implantable devices support by reducing hospital visits.

Learn more about the key segments shaping this market

Download Free PDF

Based on application, the electronic drug delivery devices market is segmented into diabetes, respiratory diseases, oncology, cardiology and other applications. Diabetes segment dominated the market with the largest revenue share of 33.9% in 2024.
 

• There is an increase in demand for the diabetes segment due to the worldwide increase in the cases of diabetes, which requires the patient to continuously consume drugs to manage their blood sugar levels. Based on the International Diabetes Federation, there are approximately 537 million adults with diabetes in 2021, projected to increase to 643 million by 2030. This increasing population is driving the adoption rate of electronic insulin delivering devices including the advanced insulin pumps and patch injectors, which offer continuous checking of glucose levels alongside automatic dosing of insulin.
   
• For example, industry leaders such as Tandem Diabetes Care and Insulet have released their respective t:slim x2 and omnipod dash systems which provide insulin through a remote programmed system, thus allowing for easier management of diabetes. Also, mobile linked and bluetooth linked insulin pumps provide ease in drug delivery to both patients and doctors allowing easier control from remote locations.
   
• Further, regulatory bodies are acknowledging the value of integrated systems for diabetes care, which has resulted in the approvals of several devices. Also, supportive reimbursement frameworks have enhanced the use of electronic drug delivery systems among patients. For instance, the Centers for Medicare & Medicaid Services (CMS) covers the supply allowance of a continuous glucose monitoring (CGM) system (Code A4238 or A4239) to beneficiaries who possess a secondary or insulin infusion pump categorized as DME and use it to display glucose data. Further, Medicare also reimburses the allowance for CGM system supplies if other non-DME gadgets (watch, smartphone, tablet, laptop, etc.) are used together with the durable CGM receiver (E2102 or E2103).

North America held a significant share of the global electronic drug delivery devices market in 2024, accounting for 43% of the total market. The region benefits from a robust healthcare ecosystem, early adoption of digital health technologies, and a growing preference for home-based therapeutic solutions.
 

The U.S. market was valued at USD 20 billion and USD 21.6 billion in 2021 and 2022, respectively. The market size reached USD 25.1 billion in 2024, growing from USD 23.3 billion in 2023.
 

• Chronic diseases coupled with the aging population is further expected to expand the market for electronic drug delivery devices in the U.S. The Centers for Disease Control and Prevention (CDC) has stated that 60% of adults are living with one chronic disease and 40% of adults have two or more chronic diseases.
   
• Further, the adoption of sophisticated autoinjectors, digital inhalers, and smart wearable infusion pumps has increased due to outpatient remote monitoring as well as heightened healthcare spending and a shift toward value-based care.
   
• In addition, availability of well-established digital health infrastructure in the U.S. further supports the use of connected medical systems, further driving the use of electronic drug delivery devices.
   

Europe electronic drug delivery devices market accounted for USD 17.5 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• The market in Europe is expanding due to an aging population and surge in cases of chronic diseases such as cancer, diabetes and others.
   
• The European Commission reported that 21.1% of the EU population was 65 years of age or older in 2022 and is expected to reach 32.5% by 2100. Such statistics suggest the rise of chronic illnesses such as COPD, multiple sclerosis, and Parkinson’s disease which fuels demand for electronic drug delivery devices.
   
• Further, countries such as Germany, France, and the UK are promoting the adoption of these devices through establishing public-private partnerships and awareness campaigns such as Federal Digital Health Initiative in Germany and MaSante2022 Digital Health Strategy in France.
   

Germany electronic drug delivery devices market is anticipated to witness considerable growth over the analysis period.
 

• Germany deals with pervasive chronic disease prevalence alongside an aging population.
   
• According to the reports by International Diabetes Federation in 2021, the country had over 8.7 million adult diabetes patients which creates an opportunity for connected insulin pens and wearable infusion pumps that enhance adherence to therapy and control blood sugar levels.
   
• Public health insurance funds for digitally supported health applications (DiGA) along with other digital health regulation policies, strong hospital systems and innovative periodontal healthcare technology ecosystems increases the utilization of smart delivery systems in chronic disease management.
   
• The government initiatives and support for telemedicine, which is expected to reach USD 503.8 billion by 2032, creates favorable reimbursement conditions under the country’s DiGA framework.
   

The Asia Pacific electronic drug delivery devices market is anticipated to grow at the highest CAGR of 9.2% during the analysis timeframe.
 

• This market is on the rise due to the increase in chronic health issues. For instance, South Asian diabetes prevalence has increased from a pooled prevalence of 11.3% in 2000–2004 to 22.3% in 2020–2024 as reported in a systematic review across the December 2024 study published by Elsevier Journal.
   
• Countries such as China and India, as well as South Korea, are quick adopters of new treatments like radiotherapy, immunotherapy, and robotic surgeries due to supportive political climates and healthcare reform, which is driving the use of electronic drug delivery devices to offer immunotherapies and biologics.
   
• In addition, regional adoption of connected drug delivery systems is being accelerated by technologically advanced care delivery systems as well as government investments in smart hospitals and AI-based patient management systems.
   
• The Asia Pacific market is also being positively impacted by enhanced regulatory policies, increased use of in-home therapy equipment, and an expanding adoption of digital healthcare.
   

China electronic drug delivery devices market is predicted to grow significantly over the forecast period.
 

• China is one of the most important contributors to the Asia Pacific market due to its exceptionally high healthcare burden, healthcare capacity, and disease prevalence. According to GLOBOCAN 2022, China reported 4.8 million new cancer cases which is 24 percent of the world's total.
   
• Moreover, frameworks like Healthy China 2030 support localization and mass deployment of electronic autoinjectors and inhalers for chronic therapies, further supporting market.
   
• In addition, development of new drug therapies and biosimilars are also driving the adoption of advanced drug delivery systems such as smart injectors and smart infusion pumps, which is further contributing to the market growth. For example, China approved total 51 biosimilars in 2023 as a result of decade of rapid developments in its biopharmaceutical industry.
   

Brazil is experiencing significant growth in electronic drug delivery devices market, driven by its expanding adoption of chronic disease management.
 

• Increasing burden of chronic diseases in Brazil is driving the demand for efficient drug delivery systems.
   
• According to GLOBOCAN 2022, Brazil recorded 627,193 new cancer cases and 278,835 related deaths. Further, 16.8 million diabetes cases were reported in 2020 according to the data from National Library of Medicine. Such statistics underline the need for advanced electronic drug delivery devices to support chronic disease management.
   
• Moreover, government-led investments in public health networks, availability of universal healthcare system (SUS), and expansion of private multispecialty hospitals are further accelerating market development.
   

Saudi Arabia electronic drug delivery devices market is poised to witness substantial growth in Middle East and Africa market during the forecast period.
 

• Saudi Arabia’s aging population is rising rapidly, with those 60 years or older increasing 5-fold from 2 million in the year 2020 i.e., 5.9% of the total population of the country to 10.5 million by 2050. Thus, a large portion of the population is at high risk of chronic illnesses such as cancer, diabetes, further fostering market growth.
   
• Alongside this increase, the growing burden of diabetes also complicates the issue as it increases the likelihood of life-threatening complications and contributes to growing use of autoinjectors and pen injectors.
   
• Further, as part of its Vision 2030 reforms, Saudi Arabia is focusing on healthcare digitalization, facilitating public-private partnerships to deploy integrated delivery platforms and home-based therapy tools across its healthcare infrastructure.
   

Electronic Drug Delivery Devices Market Share

The market for electronic drug delivery devices is moderately consolidated and is dominated by global players spanning the medical devices, pharma industries, and component manufacturing domains. Top 4 players include Medtronic, Insulet, Becton, Dickinson and Company, and Tandem Diabetes Care, which together hold approximately 40% of the market share owing to advancements in the wearable insulin pumps, patch injectors, and connected autoinjectors.
 

These firms leverage strong IPs and digital integration capabilities. Pharma companies, like Novo Nordisk, Sanofi, and Eli Lilly, are incorporating advanced connected systems within diabetes and obesity treatments, especially with integrated devices for delivery systems. Component experts, including West Pharmaceutical Services, Ypsomed, and SHL Group, are partnering more with pharmaceutical companies to develop delivery systems for subcutaneous injections because of increased need for self-administered and home care for chronic diseases.
 

Electronic Drug Delivery Devices Market Companies

Some of the eminent market participants operating in the electronic drug delivery devices industry include:

• Abbott Laboratories
• AstraZeneca
• Becton, Dickinson and Company
• Eli Lilly and Company
• Gerresheimer
• Haselmeier
• Insulet
• Medtronic
• Nemera
• Novo Nordisk
• Pfizer
• Sanofi
• SHL Group
• Tandem Diabetes Care
• West Pharmaceutical Services
• Ypsomed

• Medtronic has one of the most sophisticated wearable infusion pumps such as the MiniMed series, which is one of the most used in diabetes management and is integrated with continuous glucose monitoring systems. The company invests heavily in digital integration like Bluetooth-enabled devices and smartphone apps, which improve real-time monitoring and active patient participation.
   
• Insulet, one of the leading players in tubeless insulin pump technology, employs the Omnipod system which enhances diabetes therapy via discrete and app-controlled insulin delivery. Strengthening chronic condition management continues to drive innovation at Insulet with a focus on wireless, user-friendly, and AI-integrated advancements.
   
• Becton, Dickinson and Company has significant experience in prefilled syringes, auto-injectors, and pen injectors, that gives competitive edge while designing electronic and connected systems for treating chronic diseases.
   

Electronic Drug Delivery Devices Industry News:

• In May 2025, Tandem Diabetes Care, one of the leading company focusing on diabetes care and insulin delivery systems, announced a commercial launch of their Control-IQ+ technology, their newest hybrid closed loop algorithm, in the US. The technology is now available for children aged 2 and above with type 1 diabetes, as well as adults with type 2 diabetes, and is compatible with the t:slim X2 insulin pump and the Tandem Mobi System.
   
• In January 2025, West Pharmaceutical Services introduced Daikyo PLASCAP Ready-to-Use Validated (RUV) closures. These closures offer a low complexity, single-step vial sealing solution due to the integrated stoppers. This advanced design is expected to aid the storage and handling requirements of advanced therapeutics like gene and cell therapies.
   
• In August 2024, Insulet announced that the company had received clearance from U.S. FDA for Omnipod 5 Automated Insulin Delivery System for use in patients with type 2 diabetes of 18 years and above. This expansion enabled Omnipod 5 to be the first and only automated insulin delivery system approved for both type 1 and type 2 diabetes management.
   
• In April 2023, Medtronic announced the U.S. FDA approval for its MiniMed 780G System, which is worlds first insulin pump with meal detection technology. The pump also includes automatic adjustments and correction feature to manage sugar level every 5 minutes.
   

The electronic drug delivery devices market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Smart infusion pumps
• Smart metered dose inhalers
• Implantable drug delivery devices
• Smart transdermal patches
• Other products

Market, By Application

• Diabetes
• Respiratory diseases
• Oncology
• Cardiology
• Other applications

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands 
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE